- Home
- NXC vs MAIA Comparison
NXC vs MAIA Comparison
Compare NXC & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NXC | MAIA |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.2M | 44.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | NXC | MAIA |
|---|---|---|
| Price | $13.20 | $1.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.5K | ★ 936.4K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $70.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.86 | $0.87 |
| 52 Week High | $13.70 | $2.74 |
Technical Indicators
Market Signals| Indicator | NXC | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 52.54 | 50.66 |
| Support Level | $12.86 | $1.13 |
| Resistance Level | $13.27 | $1.75 |
| Average True Range (ATR) | 0.11 | 0.16 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 77.27 | 25.00 |
Price Performance
Historical ComparisonAbout NXC Nuveen California Select Tax-Free Income Portfolio
Nuveen CA Select Tax Free Income Port is a diversified closed-end management investment company. Its objective is to provide stable dividends exempt from both regular federal and California income taxes, consistent with the preservation of capital by investing in municipal obligations.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.